Overview

• Biotechnology firm reported Q4 net loss of $38.7 mln vs $30.8 mln loss a year ago; no collaboration revenue

• Company holds $343 mln cash, funding operations into 2028

• Company advancing vopimetostat trials in pancreatic cancer, enters new collaborations

Outlook

• Tango plans to start a pivotal study for vopimetostat in pancreatic cancer in 2026

• Initial data from vopimetostat + RAS(ON) inhibitors study expected in 2026

• Tango's cash runway extends into 2028, supporting clinical initiatives

Result Drivers

• VOPIMETOSTAT TRIALS - Strong enrollment in vopimetostat + RAS(ON) inhibitors combination study, showing early safety and efficacy

• NEW SUPPLY AGREEMENT - Tango entered a supply agreement with Erasca to evaluate vopimetostat with ERAS-0015 in clinical trials

• ROBUST CASH POSITION - Company holds $343 mln cash, funding operations into 2028

Company press release: ID:nGNXbpqw7v

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Tango Therapeutics Inc is $14.00, about 13.4% above its March 4 closing price of $12.35

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.